Navigation Links
Gut microbiota transplantation may prevent development of diabetes and fatty liver disease
Date:4/19/2012

Barcelona, Spain, Thursday 19 April 2012: Exciting new data presented today at the International Liver Congress 2012 shows the gut microbiota's causal role in the development of diabetes and non-alcoholic fatty liver disease (NAFLD), independent of obesity.(1) Though an early stage animal model, the French study highlights the possibility of preventing diabetes and NAFLD with gut microbiota transplantation the engrafting of new microbiota, usually through administering faecal material from a healthy donor into the colon of a diseased recipient.(2)

In the 16 week study, two groups of germ free mice received gut microbiota transplants; one set from donor mice displaying symptoms of insulin resistance and liver steatosis (responders), the other from normal mice (non responders). The donor mice were selected due to their response to being fed a high fat diet.

The germ free group that received microbiota from symptomatic mice (responder receivers - RR) showed higher levels of fat concentration in the liver as well as being insulin resistant. The germ free group that received microbiota from healthy mice (non-responder-receivers NRR) maintained normal glucose levels and sensitivity to insulin.

EASL Scientific Committee Member Dr Frank Lammert said: "The factors leading to Non-Alcoholic Fatty Liver Disease (NAFLD) are poorly understood, but it is known that NAFLD and Type 2 diabetes are characterised, respectively, by liver inflammation and metabolic disorders like insulin resistance."

"This study shows that different microbiota cause different metabolic responses in animals. By implanting microbiota from healthy mice, the study authors prevented the development of liver inflammation and insulin resistance, both indications of liver disease and diabetes. Thus, gut microbiota transplants could have a therapeutic role in the development of these diseases."

The RR mice also showed lower levels of microorganisms than usually found in the healthy gut. Lachnospiraceae was identified as the species most important in developing fatty liver and insulin resistance.

At present, the intestinal microbiota is considered to constitute a "microbial organ": one that has pivotal roles in the body's metabolism as well as immune function. Therefore transplantation aims to restore gut functionality and re-establish a certain state of intestinal flora.


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-789-438-6428
European Association for the Study of the Liver
Source:Eurekalert

Related biology news :

1. Gut microbiota regulates bile acid metabolism
2. New book includes advances in the science and practice of transfusion and transplantation
3. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
4. Ovarian transplantation: New technique gives greatly improved results in this delicate operation
5. Ovarian transplantation: First baby is born after a new technique
6. Rare genetic disease successfully reversed using stem cell transplantation
7. Novel Parkinsons treatment strategy involves cell transplantation
8. Cell Transplantation reports consistent and successful islet isolations offer diabetes hope
9. Coral transplantation the simple and cheap solution to reef restoration
10. Ovarian transplantation restores fertility to old mice and also lengthens their lives
11. New cell transplantation journal launched
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):
(Date:2/26/2017)... ... 2017 , ... Rob Lowe is a well recognized television personality, so it ... on issues that are important to the American public and important to society at ... a hot topic around the world for a few years. , The climate and ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an ... late 2014, FireflySci had the goal of bringing their powerful cuvette and ... shape the path that FireflySci is going on as they add yet another mark ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
Breaking Biology Technology: